3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
ImmunityBio announced on October 14, 2026 that the FDA expanded the approved indication for ANKTIVA plus BCG to include patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with papillary-only tumors. The company says this is the first FDA approval to cover that group and that access now extends to all patients with BCG-unresponsive NMIBC. The filing contains no revenue, earnings, or guidance figures, so the effect on shareholders depends on future commercial results.
FDA expanded the ANKTIVA plus BCG indication on or before October 14, 2026, adding BCG-unresponsive NMIBC with papillary-only tumors
The company states papillary disease represents approximately 85% of the NMIBC patient population
The prior FDA approval, in April 2024, covered BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors
In Cohort A of the QUILT-3.032 trial, 62% of 77 patients achieved a complete response
Mannatech told investors it believes it has regained compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement, after a deficiency notice dated April 20, 2026. The claim rests on a pro forma adjustment tied to a share purchase agreement and a tax ruling, and the auditor review and Nasdaq's own view are still pending, so the listing outcome remains uncertain for shareholders.
Stockholders' equity was $(5,223,000) per the 2025 Form 10-K and $(4,970,000) as of June 30, 2026, per the Q2 Form 10-Q, against a $2,500,000 requirement.
Mannatech's share purchase agreement gives it 100% direct ownership of Mannatech Swiss Holdings GmbH, which the company says qualifies distributions for a 5% withholding tax rate.
Nasdaq will keep monitoring; if the 10-K for the year ending December 31, 2026 does not show compliance, the company may face delisting, with a right to appeal to a Nasdaq Hearings Panel.
The Q3 2026 Form 10-Q is expected on or before November 16, 2026, and the pro forma adjustment will be reviewed by the independent auditor.
Plum Acquisition Corp. IV received a Nasdaq notice on October 7, 2026, saying it did not meet the 400 total holders requirement for continued listing on the Nasdaq Global Market. Nasdaq states the notice has no immediate effect on the listing or trading of the company's securities, but the company must submit a compliance plan and may be granted up to 180 days to regain compliance.
Nasdaq Listing Rule 5450(a)(2) requires at least 400 total holders; the company was found not in compliance.
The company has 45 calendar days to submit a plan to regain compliance.
If Nasdaq accepts the plan, an extension of up to 180 calendar days from the notice date may be granted.
The filing says there is no assurance the company will regain compliance.
Nathan's Famous said it is voluntarily supplementing its definitive proxy statement for the proposed $102.00-per-share merger with Smithfield Foods, after two stockholder lawsuits and fifteen demand letters challenged the proxy's disclosures. The company and its board deny the claims, but say the supplements aim to moot the disclosure claims and reduce litigation costs and risks before the October 23, 2026 special meeting of stockholders.
Two lawsuits were filed September 30, 2026, in the Supreme Court of the State of New York against the company and its board, and seek to enjoin the merger.
Purported stockholders delivered fifteen demand letters and two Section 220 books-and-records demands under Delaware law.
The supplemental disclosures cover executive retention discussions with the buyer and Jefferies LLC's selected companies analysis.
The special meeting of stockholders is scheduled for October 23, 2026; the merger consideration is $102.00 per share.
AMASS Brands received a Nasdaq notice on October 9, 2026, saying its common stock closed below $1.00 for 30 consecutive business days and it is out of compliance with the minimum bid price rule. The notice has no immediate effect on the listing, but if the stock does not regain compliance, the company faces possible delisting, and shareholders should note the separate market value deadline of January 19, 2027.
Bid price closed below $1.00 for 30 consecutive business days, from August 26, 2026 to October 8, 2026
Nasdaq notice received October 9, 2026; grace period to regain compliance runs through April 7, 2027
Compliance requires a closing bid price of at least $1.00 for at least ten consecutive business days
Separate Nasdaq notice of July 22, 2026 on market value requirements has a compliance deadline of January 19, 2027
Netcapital regained compliance with the Nasdaq minimum bid price rule after its closing bid price was at or above $1.00 for 10 consecutive business days, from September 23 through October 6, 2026, and Nasdaq closed the matter. The company engaged Adeptus Partners, LLC to re-audit fiscal years 2022 through 2026 because its previously issued financial statements for fiscal 2022 through 2025 should no longer be relied upon, and it has not finished evaluating the corrections that may be required. The company remains out of compliance with Nasdaq Listing Rule 5250(c)(1) for not filing its late annual and quarterly reports, so listing risk on that matter continues until a plan is accepted.
Nasdaq closed the bid price deficiency after the closing bid price was at or above $1.00 for 10 consecutive business days, September 23 through October 6, 2026.
Still out of compliance with Rule 5250(c)(1) for not filing the Form 10-K for fiscal year ended April 30, 2026 or the Form 10-Q for quarter ended July 31, 2026; plan due October 23, 2026.
Adeptus Partners, LLC engaged, with the Audit Committee approving on October 8, 2026, succeeding Fruci & Associates II, PLLC, which resigned effective August 12, 2026.
Financial statements for fiscal years 2022 through 2025 should no longer be relied upon; the scope of any restatement has not been determined.
OneMedNet Corporation received written notice from Nasdaq on October 13, 2026 that it has regained compliance with the $1.00 minimum bid price requirement, closing the matter. The company had received a deficiency letter on April 14, 2026, and the closing bid price was at least $1.00 per share for 10 consecutive business days from September 29 through October 12, 2026. The filing shows the listing issue is resolved, which removes the risk of delisting over the bid price rule.
Nasdaq notified the company on October 13, 2026 that it regained compliance with Listing Rule 5550(a)(2).
The closing bid price was at least $1.00 per share for 10 consecutive business days, September 29 to October 12, 2026.
The original deficiency notice was received April 14, 2026, with a grace period to October 12, 2026.
The matter is now closed, according to the filing signed by CEO Aaron Green.
Brightline Interactive said Nasdaq confirmed on October 12, 2026 that it has regained compliance with the $1.00 minimum bid price rule, and the matter is closed. The company stated that compliance followed a 1-for-8 reverse stock split effective September 28, 2026, and that its common stock continues to trade on the Nasdaq Capital Market as BTLN, so the filing removes the delisting threat tied to the bid price issue.
Nasdaq letter dated October 12, 2026 confirmed compliance; the closing bid price was at $1.00 or greater for 10 consecutive business days
Company effected a 1-for-8 reverse stock split, effective September 28, 2026
Nasdaq issued a Staff Determination to delist on September 11, 2026; the company requested a hearing on September 17, 2026, which stayed any delisting action
Stock continues to trade on the Nasdaq Capital Market under the symbol BTLN
On October 13, 2026, Xeris Biopharma, through subsidiary Xeris Pharmaceuticals, filed patent infringement lawsuits in federal court in New Jersey against several makers of generic dichlorphenamide, the active ingredient in its KEVEYIS product. The suits follow the grant of U.S. Patent No. 12,758,502, and the company seeks an injunction, monetary and enhanced damages, and attorneys' fees. The filing does not include financial figures, so the effect on shareholders will depend on the outcome of the litigation.
Two separate actions filed October 13, 2026, in the U.S. District Court for the District of New Jersey.
Defendants include Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Cycle Pharmaceuticals Limited, Lemed Pharmacy III, LLC, Lemed Specialty Pharmacy Arizona, LLC, Rising Pharma Holdings, Inc., and Rising Pharma Specialties Pvt. Ltd.
The suits concern U.S. Patent No. 12,758,502, related to the KEVEYIS (dichlorphenamide) product.
The company seeks a judgment of infringement, injunctive relief, monetary and enhanced damages, attorneys' fees, and costs.
Quoin Pharmaceuticals said on October 14, 2026 that the European Medicines Agency granted Orphan Drug Designation to its lead product candidate QRX003 for treating Peeling Skin Syndrome. If QRX003 is approved for marketing by the EMA, the company would receive 10 years of market exclusivity in Europe for similar medicines for this indication, and the company plans to start the first-ever formal clinical study for the condition before year end.
EMA granted Orphan Drug Designation to QRX003 for Peeling Skin Syndrome, announced October 14, 2026
Designation brings scientific advice on study protocols, various fee reductions and access to EU grants
If approved by the EMA, QRX003 would receive 10 years of market exclusivity in Europe for this indication
The company intends to initiate the first-ever formal clinical study for Peeling Skin Syndrome before year end
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.